Form 4: Director Richard Stillwell Increases Stake in Tonix

Director Richard Stillwell purchased 5,000 shares of Tonix Pharmaceuticals Holding Corp. common stock on June 8, 2026.

Summary

• Director Richard Stillwell acquired 5,000 shares of Tonix Pharmaceuticals common stock.
• The shares were purchased at a weighted average price of $11.65 per share.
• The transaction occurred through a series of open market purchases with prices ranging from $11.63 to $11.65.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level insider buying often indicates confidence in the company's future prospects.

Positives

• Insider confidence is demonstrated by a director purchasing shares with personal capital.
• The purchase reflects a commitment to the company's long-term value by a member of the board.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the price of pharmaceutical equities.
• General risks associated with the biotechnology sector.

Future Outlook

Not applicable as this is a disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal by the market, suggesting that those with the most intimate knowledge of the company's operations believe the stock is undervalued.

Comparison to Industry Standards

• Insider purchases by directors are standard corporate governance signals in the biotech industry.
• The volume of 5,000 shares is consistent with typical director-level open market acquisitions.

Stakeholder Impact

• Shareholders may view this as a positive indicator of management alignment with investor interests.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Insider Trading, Form 4, Biotech, Director Purchase